All In Biotech

NDA 022211 · Bausch and Lomb

Zirgan

Ganciclovir · Ophthalmic · Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor; Nucleoside Analog Antiviral

Orphan

Last checked: Nov 20, 2026Latest source record: Jan 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Sep 15, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

196

46 Phase 3, 21 recruiting

FAERS reports

10,361

9,837 serious, 3,155 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 18, 2026.

ZIRGAN is indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in adults and pediatric patients aged 2 years and older. ZIRGAN is a nucleoside analog antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in adults and pediatric patients aged 2 years and older. ( 1 )

Mechanism: ZIRGAN is an antiviral drug [ see Microbiology (12.4) ] .

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ZIRGAN · GANCICLOVIR 0.15% · GEL, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ganciclovir" as an intervention, any sponsor and status, largest first.

All 196 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,720
  • drug ineffective1,484
  • cytomegalovirus infection1,208
  • drug resistance678
  • pyrexia607
  • product use in unapproved indication552
  • neutropenia548
  • pancytopenia525
  • diarrhoea450
  • cytomegalovirus viraemia434
  • pneumonia429
  • sepsis420

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200473
200576
2006109
2007124
2008182
2009226
2010158
2011260
2012303
2013214
2014234
2015237
2016338
2017501
2018607
2019935
20201,023
2021938
2022858
2023850
2024848
2025799
2026466

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zirgan (Ganciclovir)

2024 spending

$9.2M

Beneficiaries

11,054

18,703 claims

Per beneficiary

$834

$93.04 per unit

View as table
YearSpending
2020$7,188,676
2021$8,521,746
2022$8,818,227
2023$9,445,994
2024$9,219,670

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 597 on PubMed

Sponsor: Bausch and Lomb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.